First Header Logo Second Header Logo

Connection

Ralph D'Agostino to Prostatic Neoplasms

This is a "connection" page, showing publications Ralph D'Agostino has written about Prostatic Neoplasms.
Connection Strength

0.703
  1. Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, D'Agostino RB, Miller LD, Sirintrapun SJ, Cramer SD, Kridel SJ. CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Mol Cancer Res. 2018 11; 16(11):1687-1700.
    View in: PubMed
    Score: 0.110
  2. Wallner LP, DiBello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, Abell JE, D'Agostino R, Loo RK, Aaronson DS, Richert-Boe K, Horwitz RI, Jacobsen SJ. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. Mayo Clin Proc. 2016 Dec; 91(12):1717-1726.
    View in: PubMed
    Score: 0.097
  3. Stuart CH, Singh R, Smith TL, D'Agostino R, Caudell D, Balaji KC, Gmeiner WH. Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. Nanomedicine (Lond). 2016 05; 11(10):1207-22.
    View in: PubMed
    Score: 0.094
  4. Hassan S, Karpova Y, Flores A, D'Agostino R, Danhauer SC, Hemal A, Kulik G. A pilot study of blood epinephrine levels and CREB phosphorylation in men undergoing prostate biopsies. Int Urol Nephrol. 2014 Mar; 46(3):505-10.
    View in: PubMed
    Score: 0.079
  5. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino R, Danial N, Datta SR, Kulik G. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 2013 Feb; 123(2):874-86.
    View in: PubMed
    Score: 0.075
  6. Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS, Xu J. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol. 2012 Dec; 62(6):953-61.
    View in: PubMed
    Score: 0.071
  7. Smith AJ, Karpova Y, D'Agostino R, Willingham M, Kulik G. Expression of the Bcl-2 protein BAD promotes prostate cancer growth. PLoS One. 2009 Jul 13; 4(7):e6224.
    View in: PubMed
    Score: 0.059
  8. Norris AM, Gentry M, Peehl DM, D'Agostino R, Scarpinato KD. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):57-64.
    View in: PubMed
    Score: 0.057
  9. Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun; 67(6):1257-61.
    View in: PubMed
    Score: 0.047
  10. Coffman LG, Parsonage D, D'Agostino R, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):570-5.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.